Thankfully none of our opinion here determines the success of cu64/67.
Clinicians will be the deciding factor for what will get used. Given this oral abstract presentation has been accepted, it appears at least some clinicians agree to its relevance otherwise it wouldn't have received airtime. It seems KOL Louise Emmett is certainly interested, not to mention Geoff Johnson have been very positive about it.
CU6 Price at posting:
$3.78 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)